<SEC-DOCUMENT>0001968582-23-000736.txt : 20231201
<SEC-HEADER>0001968582-23-000736.hdr.sgml : 20231201
<ACCEPTANCE-DATETIME>20231201192435
ACCESSION NUMBER:		0001968582-23-000736
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20231201
DATE AS OF CHANGE:		20231201

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apellis Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001492422
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				271537290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-38276
		FILM NUMBER:		231460975

	BUSINESS ADDRESS:	
		STREET 1:		100 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-977-5700

	MAIL ADDRESS:	
		STREET 1:		100 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dunlop A. Sinclair
		CENTRAL INDEX KEY:			0001721108

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		C/O APELLIS PHARMACEUTICALS, INC.
		STREET 2:		6400 WESTWIND WAY, SUITE A
		CITY:			CRESTWOOD
		STATE:			KY
		ZIP:			40014
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <!-- Generated by Workiva -->
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001721108</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001492422</issuerCik>
      <issuerName>Apellis Pharmaceuticals, Inc.</issuerName>
      <secFileNumber>001-38276</secFileNumber>
      <issuerAddress>
        <com:street1>100 Fifth Avenue</com:street1>
        <com:city>Waltham</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02451</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-977-5700</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>A. Sinclair Dunlop</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>JP Morgan Securities LLC</name>
        <address>
          <com:street1>390 Madison Avenue</com:street1>
          <com:street2>6th Floor</com:street2>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10017</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>24000</noOfUnitsSold>
      <aggregateMarketValue>1295760</aggregateMarketValue>
      <noOfUnitsOutstanding>118499945</noOfUnitsOutstanding>
      <approxSaleDate>12/01/2023</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>12/21/2012</acquiredDate>
      <natureOfAcquisitionTransaction>Private Transaction</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>24000</amountOfSecuritiesAcquired>
      <paymentDate>12/21/2012</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Epidarex Capital I, LP</name>
        <address>
          <com:street1>C/o Apellis Pharmaceuticals, Inc.</com:street1>
          <com:street2>100 Fifth Avenue</com:street2>
          <com:city>Waltham</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02451</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <saleDate>11/17/2023</saleDate>
      <amountOfSecuritiesSold>24000</amountOfSecuritiesSold>
      <grossProceeds>1176000</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>The shares filed today will be sold by Epidarex Capital I, LP,   A. Sinclair Dunlop as Managing Partner</remarks>
    <noticeSignature>
      <noticeDate>12/01/2023</noticeDate>
      <signature>/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for A. Sinclair Dunlop</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
